Zacks Research Issues Negative Estimate for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of Charles River Laboratories International in a research note issued on Tuesday, December 24th. Zacks Research analyst R. Department now expects that the medical research company will earn $2.35 per share for the quarter, down from their prior forecast of $2.42. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.18 per share. Zacks Research also issued estimates for Charles River Laboratories International’s FY2025 earnings at $9.99 EPS, Q1 2026 earnings at $2.75 EPS, Q3 2026 earnings at $2.87 EPS and FY2026 earnings at $11.60 EPS.

Several other research firms have also commented on CRL. TD Cowen raised their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Finally, Redburn Atlantic initiated coverage on Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $214.00.

Charles River Laboratories International Stock Down 0.3 %

CRL stock opened at $186.16 on Friday. Charles River Laboratories International has a 52 week low of $176.48 and a 52 week high of $275.00. The business has a 50-day simple moving average of $193.06 and a 200 day simple moving average of $201.23. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The company has a market cap of $9.52 billion, a PE ratio of 23.30, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the previous year, the firm posted $2.72 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year.

Institutional Trading of Charles River Laboratories International

Institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its holdings in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after acquiring an additional 3,738,018 shares during the period. State Street Corp grew its stake in Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after purchasing an additional 41,421 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its holdings in Charles River Laboratories International by 1.7% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock worth $394,359,000 after purchasing an additional 31,359 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after buying an additional 509,163 shares during the period. Finally, Earnest Partners LLC boosted its holdings in shares of Charles River Laboratories International by 12.4% during the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).